Answers are grounded in this paper and cite their sources.
Finding ways to target the alternative (ALT) telomere lengthening pathway found in some cancer cells could complement telomerase inhibitors currently in clinical trials.
No takes yet. Share an insight, caveat, or question.
Shay et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: